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Abstract
Since the 1990s, glycated haemoglobin (HbA1C) has been the gold standard for monitoring glycaemic
control in people diagnosed as having either type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus
(T2DM). Discussions are underway about diagnosing diabetes mellitus on the basis of HbA1C titres and
using HbA1C tests to screen for T2DM. These discussions have focused on the relative benefits for
individual patients, with some attention directed towards reduced costs to healthcare systems and
benefits to society. We argue that there are strong ethical reasons for adopting HbA1C-based diagnosis
and T2DM screening that have not yet been articulated. The rationale includes the differential impact of
HbA1C-based diabetic testing on disadvantaged groups, and what we are beginning to learn about HbA1C
vis-à-vis population health. Although it is arguable that screening must primarily benefit the individual,
using HbA1C to diagnose and screen for T2DM may promote a more just distribution of health resources
and lead to advances in investigating, monitoring and tackling the social determinants of health.
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Abstract
Since the 1990s, glycated haemoglobin (HbA1C) has been the gold standard for monitoring
glycaemic control in people diagnosed as having either type 1 diabetes mellitus (T1DM) or type 2
diabetes mellitus (T2DM). Discussions are underway about diagnosing diabetes mellitus on the basis
of HbA1C titres and using HbA1C tests to screen for T2DM. These discussions have focused on the
relative benefits for individual patients, with some attention directed towards reduced costs to
healthcare systems and benefits to society. We argue that there are strong ethical reasons for
adopting HbA1C-based diagnosis and T2DM screening that have not yet been articulated. The
rationale includes the differential impact of HbA1C-based diabetic testing on disadvantaged groups,
and what we are beginning to learn about HbA1C vis-à-vis population health. Although it is arguable
that screening must primarily benefit the individual, using HbA1C to diagnose and screen for T2DM
may promote a more just distribution of health resources and lead to advances in investigating,
monitoring and tackling the social determinants of health.

Introduction
The rising incidence of type 2 diabetes mellitus (T2DM) is a pressing global health concern. The need
to identify individuals at elevated risk of diabetic complications more reliably and earlier has
prompted discussions as to the costs and benefits of changing the diagnostic criteria from a glucosebased measure to glycated haemoglobin (HbA1C) (box 1), with a suggested threshold for diabetes of
6.5% HbA1C.1 While HbA1C measures could also be used to confirm type 1 diabetes mellitus
(T1DM), since T1DM usually presents acutely, the practical and ethical issues associated with HbA1Cbased diagnosis apply chiefly to T2DM. The primary advantage of HbA1C-based tests is that they
measure an individual's exposure to hyperglycaemic states over a period of weeks, rather than
hours, which can facilitate the identification of low levels of persistent hyperglycaemia. The other
key reason to change diagnostic techniques for diabetes is the stable relationship between an
individual's HbA1C titres and their risk of macrovascular disease. Currently, fasting plasma glucose
levels (FPG) for diagnosing diabetes are set at 7.0 mmol/l because there is a sharp inflexion at this
point for the risk of microvascular disease (renal, vision, etc.). It has not, however, been possible to
set a diagnostic criterion based on FPG to reflect risk of macrovascular disease, because an
individual's risk of cardiovascular pathologies rises gradually relative to FPG. Consequently, current
methods of diagnosing diabetes do little to mitigate the risks of macrovascular diseases in individual
cases.2 When examined from both primary care and population health perspectives, the lag
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between onset of cellular dysfunction and glucose-based clinical diagnosis (estimated at 7 years, on
average) is now thought to have a major impact on prognoses for patients with T2DM. Because
HbA1C levels can be used to predict both microvascular disease and the risks of fatal and non-fatal
macrovascular events in pre-diabetic and diagnosed cases of T2DM, the American Diabetic
Association has recently recommended that HbA1C levels should be used to define and diagnose
diabetic diseases.1
Box 1: Glycated haemoglobin (HbA1C), diabetes mellitus, cardiovascular disease and population
health
HbA1C is a blood-borne glycoprotein that forms through a direct reaction between plasma glucose
and haemoglobin. Foundational trials conducted in the 1990s established HbA1C assays as a reliable
index of glycaemic control in individuals with diabetes.3 4 More recent population-based studies
confirm that HbA1C is also a reliable marker of cardiovascular risk in both non-diabetic and diabetic
populations, although the causal role of glucose in cardiovascular disease is as yet unclear.5 Social
epidemiologists have used HbA1C as a biological measure to compare with self-rated health. Studies
have consistently found raised HbA1C levels associated with increased exposure to stressors in nondiabetic individuals and that there is an inverse and independent relationship between raised HbA1C
and socioeconomic status and social disadvantage.6 7 Hence HbA1C is a stable biomarker of an
individual's exposure to hyperglycaemic states and cardiometabolic risks, even in patients without
measurable abnormalities in glucose metabolism or who are below the threshold for clinical T2DM.
The move to HbA1C-based diagnosis is pragmatic. The aim is to identify at-risk individuals earlier,
well before they have clinically evident glucose dysregulation and an elevated risk of diabetic
complications.

Current practices and debates surrounding T2DM screening, diagnosis and prevention
Diagnosis and screening are distinct types of clinical practice. Diagnosis is a process of identifying
potential abnormalities in an affected individual seeking healthcare, whereas screening is used to
identify members of a population who have a specific condition, or are at heightened risk of
developing it, but who are not specifically seeking treatment. Diagnosis generally presupposes some
form of intervention, whereas screening may focus the attention of individuals, care providers and
policy makers on preventive actions. Clinical screening for T2DM has generally only been undertaken
on an ad hoc and opportunistic basis in most developed nations. As evidence continues to emerge
that earlier diagnosis and treatment of hyperglycaemia and related metabolic abnormalities is
beneficial,8 9 a growing number of professional organisations are advocating targeted screening for
T2DM in high-risk populations.10 Past attempts to screen for these conditions have been haphazard,
relied on a variety of different tests and cut-offs, and have had variable success. Although the utility
of population-level screening for T2DM remains controversial, the emerging consensus is that
HbA1C may be a better screening tool than the alternatives.11 12 Systematic use of HbA1C assays
may prove to be a powerful secondary prevention measure, as the earlier identification of at-risk
and pre-diabetic individuals provides those affected and their primary care providers with a better
chance of avoiding the onset, risks and burdens of diabetic complications (assuming that relevant
services are available).
Past reluctance to adopt HbA1C as a diagnostic criterion for T2DM reflected legitimate concerns
about technological standardisation, which have now been met. Like any test, HbA1C assays have
limitations, but in terms of stability, accuracy and precision, they are now considered the equal of
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standard glucose-based testing protocols.1 13 As well as providing a longitudinal measure of
hyperglycaemia and macrovascular risks, there are practical advantages to HbA1C testing. HbA1C
testing procedures are convenient. They do not require the patient to fast, and the assay can readily
be bundled with other tests, unlike oral glucose tolerance tests (OGTT) and FPG measurements.
HbA1C is an accurate test for hyperglycaemia and can be easily and immediately administered in
primary care settings. In contrast, FPG and OGTTs are intrusive, can be difficult to interpret, and rely
on high levels of patient compliance. FPG and OGTT also result in substantial under-diagnosis;
epidemiological surveys consistently estimate this to be as high as 30–50% of all cases.11
HbA1C and social epidemiology
As well as being a direct measure of glycaemic levels, HbA1C titres have been used as a measure of
population health unrelated to T2DM screening. Such research sought to investigate social
inequalities in disease prevalence and outcomes associated with social gradients, which were
otherwise unexplained by classic behavioural dimensions of health risk exposure. Social
epidemiologists used HbA1C as a biomarker to compare with individuals' self-rated health, reflecting
relative intensity and health effects of the social environment and psychosocial stress in populations
and subpopulations. Studies have consistently found raised HbA1C levels associated with increased
exposure to stressors in non-diabetic individuals, and identified an inverse and independent
relationship between raised HbA1C and socioeconomic status and social disadvantage.6 7 Because
of this association, aggregated databases of HbA1C stand to provide population risk measures, and
vital insights into how the health of entire populations is influenced by social determinants, including
emotional well-being, social networks and characteristics of where people live. The potential to use
a biological measure such as HbA1C to assess the relative health and exposure to stressors in
different populations has important implications in health policy formation and for the allocation of
scarce resources.
Ethical grounds for adopting HbA1C as the diagnostic screening test for T2DM
While the evidentiary and practical advantages of using HbA1C as a diagnostic screen for T2DM and
as a measure of population health are matters for careful and considered discussion, we argue that
the test has ethical advantages over existing clinical practices. These advantages occur for individuals
in primary care settings, and at the level of research, planning and intervention to improve the
overall health of populations (Box 2).
Box 2: A case study
The value of these kinds of data is illustrated by recent research conducted with black military
veterans living with T2DM in Philadelphia, USA. The findings from this research showed that patients
who perceived their neighbourhoods as places where people work together for improvements
tended to have lower HbA1C scores than those who did not perceive their neighbourhoods in this
way.32 As perceptions of neighbourhoods are modifiable, this study suggests that interventions
aimed at improving perceptions by fostering experiences of community inclusion and social support
could prove to be important for preventing the onset of T2DM, as well as of related health problems.
Screening and diagnosis in primary care
Screening a population for a disease is not necessarily a benign activity; it can cause harms as well as
provide benefits. Aside from the risks of false positives and unnecessary interventions, the mere
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invitation to undergo a medical procedure can change people's image of themselves, thereby
challenging and even violating their personal integrity.14 There is some ethical consensus around
the view that the benefits of a screening programme must accrue to those individuals who take part,
rather than to third parties. Participation in a screening programme should reflect an autonomous
choice, informed by a clear understanding of the possible individual benefits and harms.15 Recent
research has largely allayed concerns that informed consent deters participation, or causes
unnecessary anxiety or an unwarranted sense of insecurity for those who choose to be screened.16
17 In relation to screening for T2DM, early detection seems to be beneficial for the individual,
especially if microvascular risks, macrovascular risks and metabolic abnormalities can be mitigated
by lifestyle changes. Thus the potential harms of offering screening for T2DM to a targeted
population appear to be outweighed by the benefits. Notwithstanding the limits of autonomous
choice as an ethical framework,18 there remains ethical concern about how best to provide
disadvantaged and ‘at-risk’ groups access to screening programmes.19 20
HbA1C-based screening may be superior to glucose tests for addressing this concern. The test is
more convenient for the patient and far simpler to understand than the complicated protocols and
confusing classifications that surround glucose-based tests and diagnostic categories. This leads to
two consequences. First, as the costs and benefits of diabetes screening with HbA1C are more easily
explained to individual patients than are the alternatives (i.e., FPG and OGTT protocols), there is an
increased likelihood that those being tested will give valid informed consent for screening
procedures. Second, HbA1C, as a simpler testing regimen than the alternatives, has the potential to
make diagnostic procedures—whether it is a screen for an asymptomatic individual or a test to
confirm the T2DM diagnosis—more accessible to socially disadvantaged groups and to those unable
to comply readily with complicated test regimens.16 HbA1C assays facilitate opportunistic screening,
thereby avoiding a loss to follow-up of those who do not return for confirmatory diagnostic tests (as
is required for FPG and OGTT protocols), but who would be willing and able to fill a prescription, to
modify their diets, or to become more physically active based on diagnostic test results delivered in
a timely fashion. Moreover, even when individuals do not benefit from continuity of care or from
medical technologies such as pharmaceuticals to lower blood sugar levels, diagnostic and screening
data derived can enable population surveillance and related interventions (eg, improving access to
healthcare among disadvantaged social groups).
Adopting HbA1C as the diagnostic criterion for diabetes may promote a better balance between the
core values and principles that underpin current conceptions of ethical clinical practice. Early
identification of those at risk provides scope for the timely formation of interpersonal provider–
patient relationships, attention to social processes, and concern for life plans. All these features are
now considered to be central to effective, efficacious and respectful care of people with long-term
conditions.21 22 HbA1C screening may more easily meet the requirements of non-maleficence and
beneficence compared with alternatives, as more accurate testing and earlier diagnosis is likely to
promote more favourable outcomes for high-risk individuals. The only caveat to this claim is that the
lifestyle risks that promote T2DM must be modifiable. If it turns out that disadvantaged individuals
are unable to address the drivers of macrovascular diseases, then the increasing incidence of these
conditions among these groups could serve to highlight the need for structural reforms and
population-level interventions.
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Extending diabetic research to disadvantaged populations
Another potential ethical benefit of HbA1C screening is that it may promote greater justice in
research by facilitating the inclusion of socially disadvantaged groups in evaluating the effectiveness
of approaches to diabetic management relevant to their situations.
Disadvantaged groups are at highest risk for incidence of T2DM, for related complications, and for
comorbidities. Members of these groups often have low health literacy, experience low levels of
provider access, face significant psychosocial stressors, and struggle to manage the extra burdens
imposed by diabetes treatment.23 These groups are far less likely to have access to appropriate and
effective interventions for pre-diabetes and T2DM,24 and generally less likely to participate in and
benefit from relevant T2DM research, which currently focuses on pharmacological interventions and
modifying the behavioural patterns of individual patients. While emerging evidence indicates that
earlier intervention can provide for sustained prevention of T2DM,25 the challenge is to translate
these findings to the ‘real’ world.26 To the extent that lifestyle risks are modifiable, then there is a
strong likelihood that disadvantaged populations would disproportionately benefit, and do better
with earlier diagnosis.
Yet the research evidence that informs these types of individually focused clinical interventions may
not reflect the circumstances and needs of disadvantaged groups. This kind of mismatch can occur
through a lack of representation in research design, and through exclusion criteria such as presence
of comorbidities and participant availability, leading to a lack of evidence that is applicable to those
excluded from studies. Given the importance of research evidence in informing resource allocation
decisions and policy development, the lack of evidence as to effectiveness in disadvantaged
populations is a serious issue that compromises access to care and health equity.27 Using HbA1C as
a research tool could facilitate the inclusion of disadvantaged groups in relevant studies, thereby
avoiding these potential harms. Moreover, it is likely that making these services accessible to those
who need them most will benefit the whole of society, through development of more equitable
service models and lower rates of morbidity and mortality.28
Beyond their facility as a tool to evaluate interventions in primary care settings and members of
hard-to-reach populations, HbA1C titres are also a useful gauge of population health, including the
effects of exposure to environmental stressors. Modest increases in the level of HbA1C have been
correlated with key measures of socioeconomic status and job stress,6 potentially contributing to
increased risk of heart disease and other morbidities in non-diabetic populations. The systematic
collection of HbA1C information to create population health databases has potential for opening up
new ways of investigating the complex pathways through which socioeconomic and structural
factors impact on health. Although our understanding of the mechanisms through which social
environments affect health remains limited and partial, the available evidence suggests that social
relationships and social dimensions of environments may have significant effects on the success or
failure of attempts to address burdens of chronic disease in diabetic and non-diabetic individuals.
The link between HbA1C levels and macrovascular risks is potentially of great significance because
most people with diabetes, and many without diabetes, will die from macrovascular disease.5 At the
same time, microvascular risks such as vision loss and kidney failure are often dreaded more than
macrovascular risks by individuals with diabetes.29 Elevated HbA1C levels correlate with both
macrovascular and microvascular risks, and also appear to have value vis-à-vis measuring the impact
of exposure to stressors. For these reasons, using HbA1C to diagnose and screen for T2DM could
effectively address the ethical tensions between population- and individual-level priorities in
screening.
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If HbA1C proves to be a reliable research tool investigating the links between health and the social,
economic and cultural circumstances of disadvantage, there are potential benefits, including novel
intervention methods and increased opportunities for understanding and addressing the effects of
disadvantage on health. The creation of population health databases of HbA1C could further these
aims.30 For example, a population map identifying areas of raised HbA1C could inform social
interventions, again with greatest benefit to the worst-off.31 HbA1C-based testing may provide a
greater differential benefit for disadvantaged groups through a timelier diagnosis of insulin
intolerance; in addition, because HbA1C also reflects the effects of other macrovascular risk factors,
the systematic collection of these data may have a differential impact on the prioritisation of health
outcomes at the level of populations. If this then leads to the greatest benefits accruing to the most
disadvantaged, it is possible that HbA1C may promote greater justice in healthcare.
The case for Hb1AC testing and evidence-based social medicine
Thirty years ago, Geoffrey Rose argued that medicine has a duty of care not only to individual
patients but also to the communities and populations to which we all belong.33 Social relationships
and environments appear to exert direct influences on major causes of mortality, including from
cardiovascular disease.34 Therefore, non-medical determinants of population health deserve our
attention when discussing the relative merits of diagnostic tests for T2DM. While we must ensure
that targeted individuals are the beneficiaries of screening programmes, not all of these benefits
need be direct. We should also consider the potential for benefits to the health of populations, as,
after all, individuals stand to benefit from improvements in population health.
Addressing the social determinants of health and the associated health gradient is a matter of
justice; however, it is difficult for healthcare providers to address broader issues of justice, as their
focus is on individual patients presenting for care. Nonetheless, HbA1C data may be suited to
providing the type of evidence base and evaluative framework necessary to broaden the focus of
macrovascular disease prevention and treatment interventions beyond clinical settings.
With the routine availability of HbA1C administrative data derived from screening for T2DM as well
as from monitoring people diagnosed with T2DM, it would be possible to measure longitudinally the
overall population health impact of social interventions such as community development initiatives
and to compare the cost-effectiveness of social interventions with pharmaceutical treatments. Given
that the net impact of patient self-management on the health gradient is likely to be very small,35
inequities in outcomes for T2DM and macrovascular disease are unlikely to lessen significantly,
unless these new forms of evidence can be generated, evaluated and integrated into established
systems.23
Conclusion
HbA1C-based testing for T2DM has significant practical and ethical benefits over existing diagnostic
and screening protocols. HbA1C testing for T2DM should improve access to care for disadvantaged
populations - who are at heightened risk of and over-represented among people with T2DM. Any
step that leads to greater inclusion of these groups is likely to promote greater justice in healthcare
provision, research and planning. At the same time, the wealth of data created from populationlevel HbA1C screening also has the potential to allow us to better investigate, monitor and reduce
the structurally embedded causes of population-level health inequities.
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